Skip to content
Screener

Dyne Therapeutics, Inc. DYN Retained Earnings

Retained Earnings at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-$4.55B-2.0%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$2.84B-24.9%
Arrowhead Research logo
Arrowhead ResearchARWR
-$1.73B-21.1%
Wave Life Sciences logo
Wave Life SciencesWVE
-$1.42B-16.6%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
-$1.07B-24.0%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
-$595.38M-42.0%

Other financials

Income statement

See full
Operating income-$125.3M-2.4%
Net income-$120.9M-4.8%
EPS (diluted)-$0.73+30.5%

Balance sheet

See full
Cash & equivalents$753.1M+59.5%
Total debt$168.7M+623%
Total equity$865.1M+29.3%
Total assets$1.1B+49.8%

Cash flow

See full
Operating cash flow-$144.9M-36.9%
CapEx$221.0K-77.5%
Free cash flow-$145.1M-35.8%

Valuation

See full
Market cap$4.83B+193%
Enterprise value$4.25B+231%

Returns & leverage

See full
Return on equity-58.9%-4.4pp
Debt / equity0.2×+0.2×
Current ratio19.9×-0.4×

Where this comes from

Reported directly by Dyne Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The source filing: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 7:25 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-215702
Line itemMarch 31, 2026December 31, 2025
Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025
Common stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2026 and December 31, 2025; 165,201,329 and 164,950,540 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively1616
Additional paid-in capital2,382,1722,367,780
Accumulated other comprehensive loss (gain)(137)475
Accumulated deficit(1,516,996)(1,396,142)
Total stockholders’ equity865,055972,129
Total liabilities and stockholders’ equity$1,079,950$1,186,958

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Dyne Therapeutics, Inc.'s retained earnings?
Dyne Therapeutics, Inc. (DYN) reported retained earnings of -$1.52B in Q1 2026.
How has Dyne Therapeutics, Inc.'s retained earnings changed year-over-year?
Dyne Therapeutics, Inc.'s retained earnings decreased by 42.4% year-over-year, from -$1.07B to -$1.52B.
What is the long-term trend for Dyne Therapeutics, Inc.'s retained earnings?
Over 5 years (2020 to 2025), Dyne Therapeutics, Inc.'s retained earnings has grown at a 77.5% compound annual growth rate (CAGR), from -$79.18M to -$1.4B.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.

Ask your AI about Dyne Therapeutics, Inc.'s retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude